Antifibrinolytics in liver transplantation: They are effective, but what about the risk-benefit ratio?
Open Access
- 30 January 2004
- journal article
- editorial
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 10 (2) , 285-288
- https://doi.org/10.1002/lt.20077
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: A comparative study †Liver Transplantation, 2004
- Intraoperative red blood cell transfusion in liver transplantation: Influence on patient outcome, prediction of requirements, and measures to reduce themLiver Transplantation, 2003
- Pharmacological Strategies to Decrease Transfusion Requirements in Patients Undergoing SurgeryDrugs, 2002
- Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: A prospective, randomized, double-blind studyLiver Transplantation, 2001
- Tranexamic Acid Reduces Red Cell Transfusion Better than ε-Aminocaproic Acid or Placebo in Liver TransplantationAnesthesia & Analgesia, 2000
- Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind studyThe Lancet, 2000
- Tranexamic Acid Reduces Blood Loss, Transfusion Requirements, and Coagulation Factor Use in Primary Orthotopic Liver TransplantationAnesthesiology, 1996
- EFFECT OF APROTININ ON INTRAOPERATIVE BLEEDING AND FIBRINOLYSIS IN LIVER TRANSPLANTATIONThe Lancet, 1989
- Hemostasis in liver transplantationGastroenterology, 1989
- SYSTEMIC EFFECTS OF TISSUE PLASMINOGEN ACTIVATOR-ASSOCIATED FIBRINOLYSIS AND ITS RELATION TO THROMBIN GENERATION IN ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 1989